Sartorius Stedim Biotech S.A. (ETR:56S1)

Market Cap	18.32B -8.5%
Revenue (ttm)	2.95B +7.7%
Net Income	263.90M +64.3%
EPS	2.71 +61.1%
Shares Out	n/a
PE Ratio	69.43
Forward PE	37.11
Dividend	0.69 (0.36%)
Ex-Dividend Date	Apr 2, 2025

Volume	8
Average Volume	81
Open	191.60
Previous Close	197.65
Day's Range	191.60 - 191.60
52-Week Range	150.90 - 227.90
Beta	n/a
RSI	32.93
Earnings Date	Feb 3, 2026

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiolog...

• Industry: Laboratory Analytical Instruments
• Founded: 1978
• Employees: 10,134
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 56S1

Financial Performance

In 2024, Sartorius Stedim Biotech's revenue was 2.78 billion, an increase of 0.16% compared to the previous year's 2.78 billion. Earnings were 175.10 million, a decrease of -43.57%.